5-methoxy-1-oxo-indan-2-carbaldehyde | 952006-66-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-methoxy-1-oxo-indan-2-carbaldehyde
• 英文别名: 5-Methoxy-1-oxo-indan-2-carbaldehyd；6-Methoxy-3-oxo-1,2-dihydroindene-2-carbaldehyde
• CAS: 952006-66-5
• 化学式: C₁₁H₁₀O₃
• 分子量: 190.199
• InChiKey: VIQWDFAWHLYXNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methoxy-1-oxo-indan-2-carbaldehyde 在 一水合肼 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成
  参考文献：
  名称：

  芳基取代或芳基稠合的N-羟乙基和N-羟基甲基吡唑衍生物作为雌激素受体的潜在配体的合成

  摘要：

  针对它们的雌激素活性，设计了一系列新的N-羟乙基吡唑（12a - f）和N-羟甲基吡唑衍生物（15a - f），两个羟基之间的距离为11.0±0.5Å，类似脂肪族-OH和酚类-OH 17β-雌二醇（E2）作为内源激素。为了合成标题化合物，将关键中间体1,3-二羰基衍生物（2和8）用水合肼处理，生成吡唑环5和9。后者的进一步羟烷基化产生标题吡唑。通过二维NOE NMR光谱确定产物中羟乙基或羟甲基取代基的位置。

  DOI：

  10.1007/s13738-012-0126-z
• 作为产物：
  描述：

  5-甲氧基茚满 在 chromium(VI) oxide 、 sodium methylate 、 溶剂黄146 、 苯 作用下， 生成 5-methoxy-1-oxo-indan-2-carbaldehyde
  参考文献：
  名称：

  A Glucomannan and Chitosan Fiber Supplement Decreases Plasma Cholesterol and Increases Cholesterol Excretion in Overweight Normocholesterolemic Humans

  摘要：

  Objective: Both chitosan and glucomannan have demonstrated hypocholesterolemic effects. A recent study in rats indicates that the combination of the two is also a potent hypocholesterolemic agent that increases fecal fat excretion. The objective of the present study was to determine the hypocholesterolemic effect of a supplement containing equal amounts of chitosan and glucomannan on blood lipid concentrations and fecal excretion of fat, neutral sterols and bile acids.Methods: Twenty-one overweight normocholesterolemic subjects (I I males and 10 females) were fed 2.4 g/day of a supplement containing equal amounts of chitosan and glucomannan. Prior to taking the supplement (initial period) and after 28 days (final period), blood was drawn for measurement of serum lipids and a three-day fecal sample collected for determination of fat, neutral sterol and bile acid excretion. Subjects maintained their normal dietary and activity patterns during the study.Results: Caloric intake and intake of fat and dietary fiber (excluding the supplement) did not differ between the initial and final periods. Serum total, HDL and LDL cholesterol concentrations were significantly lower (P < 0.05) in the final period compared to the initial period. Serum triacylglycerol concentration did not change between periods. There was a trend towards greater fecal excretion of neutral sterols and bile acids (p = 0.13 and 0.16, respectively) in the final period. However. fecal fat excretion did not differ between periods.Conclusions: Serum cholesterol reduction by a chitosan/glucomannan supplement is likely mediated by increased fecal steroid excretion and is not linked to fat excretion.

  DOI：

  10.1080/07315724.2002.10719246

文献信息

• A Plan for Distinguishing between Some Five- and Six-membered Ring Ketones
  作者：William S. Johnson、Wesley E. Shelberg

  DOI：10.1021/ja01226a038

  日期：1945.10
• Synthesis of aryl-substituted or aryl-fused N-hydroxyethyl and N-hydroxymethypyrazole derivatives as potential ligands for the estrogen receptor
  作者：Maryam Allahyari-Devin、Behnam Abedi、Latifeh Navidpour、Abbas Shafiee

  DOI：10.1007/s13738-012-0126-z

  日期：2013.2

  N-hydroxyethylpyrazole (12a–f) and N-hydroxymethylpyrazole derivatives (15a–f) were designed for their estrogenic activities, having a 11.0 ± 0.5 Å distance between their two hydroxyl groups, aliphatic–OH and phenolic–OH similar to 17β-estradiol (E2) as an endogenous hormone. To synthesize the title compounds, the key intermediate 1,3-dicarbonyl derivatives (2 and 8), were treated with hydrazine hydrate to produce

  针对它们的雌激素活性，设计了一系列新的N-羟乙基吡唑（12a - f）和N-羟甲基吡唑衍生物（15a - f），两个羟基之间的距离为11.0±0.5Å，类似脂肪族-OH和酚类-OH 17β-雌二醇（E2）作为内源激素。为了合成标题化合物，将关键中间体1,3-二羰基衍生物（2和8）用水合肼处理，生成吡唑环5和9。后者的进一步羟烷基化产生标题吡唑。通过二维NOE NMR光谱确定产物中羟乙基或羟甲基取代基的位置。
• A Glucomannan and Chitosan Fiber Supplement Decreases Plasma Cholesterol and Increases Cholesterol Excretion in Overweight Normocholesterolemic Humans
  作者：Daniel D. Gallaher、Cynthia M. Gallaher、Gregory J. Mahrt、Timothy P. Carr、Carolyn H. Hollingshead、Robert Hesslink、John Wise

  DOI：10.1080/07315724.2002.10719246

  日期：2002.10

  Objective: Both chitosan and glucomannan have demonstrated hypocholesterolemic effects. A recent study in rats indicates that the combination of the two is also a potent hypocholesterolemic agent that increases fecal fat excretion. The objective of the present study was to determine the hypocholesterolemic effect of a supplement containing equal amounts of chitosan and glucomannan on blood lipid concentrations and fecal excretion of fat, neutral sterols and bile acids.Methods: Twenty-one overweight normocholesterolemic subjects (I I males and 10 females) were fed 2.4 g/day of a supplement containing equal amounts of chitosan and glucomannan. Prior to taking the supplement (initial period) and after 28 days (final period), blood was drawn for measurement of serum lipids and a three-day fecal sample collected for determination of fat, neutral sterol and bile acid excretion. Subjects maintained their normal dietary and activity patterns during the study.Results: Caloric intake and intake of fat and dietary fiber (excluding the supplement) did not differ between the initial and final periods. Serum total, HDL and LDL cholesterol concentrations were significantly lower (P < 0.05) in the final period compared to the initial period. Serum triacylglycerol concentration did not change between periods. There was a trend towards greater fecal excretion of neutral sterols and bile acids (p = 0.13 and 0.16, respectively) in the final period. However. fecal fat excretion did not differ between periods.Conclusions: Serum cholesterol reduction by a chitosan/glucomannan supplement is likely mediated by increased fecal steroid excretion and is not linked to fat excretion.